Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

Novel therapies are needed for effective treatment of AML. In the relapsed setting, prognosis is very poor despite salvage treatment with chemotherapy. Evidence suggests that leukemic stem cells (LSCs) cause relapse. The cell surface receptor CD123 is highly expressed in blast cells and LSCs from AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonnevaux, Hélène, Guerif, Stephane, Albrecht, Jana, Jouannot, Erwan, De Gallier, Thibaud, Beil, Christian, Lange, Christian, Leuschner, Wulf Dirk, Schneider, Marion, Lemoine, Cendrine, Caron, Anne, Amara, Céline, Barrière, Cédric, Siavellis, Justine, Bardet, Valérie, Luna, Ernesto, Agrawal, Pankaj, Drake, Donald R., Rao, Ercole, Wonerow, Peter, Carrez, Chantal, Blanc, Véronique, Hsu, Karl, Wiederschain, Dmitri, Fraenkel, Paula G., Virone-Oddos, Angéla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409758/
https://www.ncbi.nlm.nih.gov/pubmed/34484869
http://dx.doi.org/10.1080/2162402X.2021.1945803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409758/
https://www.ncbi.nlm.nih.gov/pubmed/34484869
http://dx.doi.org/10.1080/2162402X.2021.1945803

Ejemplares similares